Articles tagged with Crohn Disease
Dr. David H. Ballard, MD, has been awarded a $100,000 grant from the SNMMI Mars Shot Research Fund to develop novel PET/MR imaging techniques for metabolic activity and inflammation in Crohn's disease. The study aims to improve biologically informed decision-making and guide treatment decisions.
Researchers have uncovered unusual clustering of endothelial cells around immune cells, signaling the start of excessive collagen production and scarring. This discovery could lead to new treatments for fibrosis, a common complication in Crohn's Disease affecting 10-20% of patients.
A new experimental rat model reproduces creeping fat in Crohn's disease, characterized by mesocolic adipose tissue hyperplasia with macroscopic, histological, immunological, and molecular similarities to human disease. The model supports the hypothesis that intestinal microbiota contributes to remodelling of mesenteric adipose tissue.
A new Danish study found that people with a higher genetic risk of developing chronic inflammatory bowel disease are more likely to experience a severe course. The researchers discovered a correlation between genetics and disease severity, which could lead to tailored treatment strategies.
A study by NYU researchers found that children with Crohn’s disease have a unique microbiome signature, characterized by more pro-inflammatory and less protective bacteria. This could lead to personalized treatments for pediatric Crohn’s disease.
A global study found that a group of bacteria, CAG-170, consistently appeared in high numbers in the gut microbiomes of healthy individuals. This species has the capacity to produce Vitamin B12 and break down carbohydrates, suggesting it plays a crucial role in maintaining human health.
A new survey by the Crohn's & Colitis Foundation found that 93% of people with inflammatory bowel disease (IBD) or at risk for it would be interested in a test to predict their risk of developing IBD. Lifestyle interventions, such as diet and exercise, were preferred over pharmaceutical approaches.
Researchers at UC Riverside find that faulty gene PTPN2 increases susceptibility to harmful bacteria like AIEC, leading to gut inflammation and IBD. The studies suggest that restoring PTPN2 function or using medications like JAK inhibitors may help control harmful bacterial growth.
Insilico Medicine presents three abstracts at the 2026 Crohn's & Colitis Congress highlighting clinical, preclinical safety, and efficacy data for ISM5411. The first-in-human Phase 1 results show no serious adverse events or deaths reported, with a favorable pharmacokinetic profile supporting gut restriction.
A new diet option has been shown to improve both physical symptoms and biological indicators of mild-to-moderate Crohn's disease. Participants in the fasting mimicking group experienced significant declines in fecal calprotectin, a protein indicating gut inflammation, and showed clinical benefits even after just one cycle.
Researchers have developed a blood test that can predict Crohn's disease years before symptoms appear. The test measures immune response to flagellin, a protein found on gut bacteria, which is elevated in individuals long before they develop the disease.
A new international study found significant changes in gut bacteria at the onset of inflammatory bowel disease (IBD), a condition that affects the digestive system. The study reveals a loss of beneficial anaerobic bacteria and an increase in oxygen-tolerant bacteria, which may trigger inflammation.
The Algae for Health in Food and Pharma summit explores the latest developments in algae cultivation and processing, food innovation, and pharmaceutical applications. The event aims to advance the understanding of algae's health potential and highlight its applications across the food and pharmaceutical sectors.
A multinational study found PSC prevalence among Asian IBD patients to be markedly lower than in Western countries, associated with more favorable clinical outcomes. The proportion of asymptomatic PSC cases has increased due to improved imaging modality detection, allowing for early-stage diagnosis and reduced liver transplantation rates.
The American Gastroenterological Association has released an updated clinical guideline on the pharmacological management of moderate-to-severe Crohn’s disease, recommending early use of high-efficacy therapies to improve patient outcomes. The guideline organizes treatments by efficacy to simplify decision-making for gastroenterologist...
Researchers at UGA engineered a live bacterium to deliver Levodopa steadily from the gut to the brain, alleviating motor deficits in models of Parkinson's disease. This breakthrough could lead to fewer pills, steadier symptom control, and better quality of life for patients.
Renowned gastroenterologist Jean-Frédéric Colombel, MD, will deliver the 31st Anatomy Lesson on November 20, exploring Mount Sinai's pioneering work in IBD prevention and treatment. His presentation aims to highlight the growing problem of immune diseases, including Crohn's disease.
Researchers at UC San Diego School of Medicine developed an AI-powered approach to decode macrophage gene expression patterns. They identified a 53-gene signature that separates reactive from tissue-healing macrophages, resolving a longstanding debate in Crohn's disease.
Researchers analyzed 659 posts on Reddit to better understand the role of social media in managing inflammatory bowel disease. The study found that patients use social media to track symptoms, manage medications, and cope with stress.
Researchers discovered a new enzyme produced by Bacteroides fragilis that activates pain signaling. The enzyme is targeted with nanoparticles to develop treatments for gut pain in inflammatory bowel disease and irritable bowel syndrome. The studies aim to restore balance between good and bad bacteria to reduce symptoms.
Double negative T cells (DNT cells) play an indispensable role in suppressing intestinal inflammation, acting as antigen-presenting cells. Their impaired function may contribute to the pathogenesis of Crohn’s disease, suggesting they could be a potential therapeutic target.
Researchers at uOttawa are developing an AI tool to provide personalized dietary strategies for people living with inflammatory bowel disease (IBD). The project aims to match specific types of carbohydrates to individual patients' unique gut microbiomes.
The Crohn's & Colitis Foundation has launched GLIDE, an integrated global registry to connect patient data from IBD registries worldwide. This initiative aims to accelerate insights into complex clinical questions, driving improvements in care for those living with Crohn's disease and ulcerative colitis.
A study by Stanford Medicine researchers reveals that creeping fat, a type of abnormal adipose tissue, forms scars in the intestines of people with Crohn's disease. This triggers debilitating scarring, which worsens symptoms and treatment options for patients.
Researchers discovered that smoking produces metabolites that encourage mouth bacteria to grow in the large intestines, triggering an immune response. These bacteria, specifically Streptococcus mitis, help reduce inflammation in ulcerative colitis by triggering a specific immune response.
A large-scale study published in PLOS Medicine found no association between early life antibiotic exposure and the development of autoimmune diseases in children. Researchers analyzed data from over 4 million Korean children and discovered no increased risk of Type 1 diabetes, Juvenile idiopathic arthritis, or other autoimmune conditions.
Researchers at ETH Zurich and Stanford University quantified the number of molecules produced by gut bacteria that reach the human body daily. This knowledge helps understand how the gut microbiome influences health and behavior.
A new study led by Mount Sinai researchers has identified distinct biological signatures in patients with mild Crohn's disease, which may help avoid overtreatment and guide more personalized care. The findings suggest that these biomarkers can distinguish mild disease from more aggressive forms, potentially allowing for safer treatment...
A study by University of California, Riverside researchers found that inhaling agricultural dust can alter the gut microbiome and impair intestinal function, leading to increased 'leaky gut' and associated chronic diseases. The study highlights the need for protective measures for agricultural workers.
The study found that guselkumab significantly improved endoscopic response and deep remission in patients with Crohn's disease. The therapy also demonstrated a corticosteroid-sparing effect, making it a valuable alternative to long-term steroid use.
A large prospective study found that a healthy plant-based diet is associated with an 8% lower risk of ulcerative colitis and a 14% lower risk of Crohn’s disease. Fruits and vegetables were identified as key protective factors against inflammatory bowel disease.
A study has discovered a connection between ferroptosis, a type of iron-dependent cell death, and inflammatory bowel disease. Lipid ROS activate ferroptosis, which drives cell death in the colon lining, and inhibiting this process may lead to new treatment options for IBD.
Researchers identified a gene mutation that disrupts iron absorption in patients with Crohn's disease, leading to persistent anemia. The study sheds light on how genetic risk factors for IBD can compound patient symptoms by interfering with nutrient absorption.
A study in Gastroenterology Nursing found that popular IBD-related TikTok videos have very low scores for quality of medical information, despite their high views. The research suggests that tailored educational content on IBD can be created for the platform, addressing gaps in IBD education.
A global study describes four distinct stages of inflammatory bowel disease (IBD) as it spreads to newly developing regions in Africa, Asia, and Latin America. The research provides resources and guidance for local healthcare systems coping with the growing burden of IBD patients.
A new approach, GlycoCaging, delivers medicine directly to the lower gut at significantly lower doses than current treatments, potentially helping people with inflammatory bowel disease. The technique has been shown to be effective in mice and has potential for treatment in humans, as most people have the ability to activate the drugs.
Researchers from UCalgary and Chinese University of Hong Kong found that IBD progresses through four predictable epidemiological stages as it spreads globally. The study forecasts a major rise in IBD prevalence in Canada by 2045, with countries in North America, Europe, and Oceania reaching Stage 3 (compounding prevalence). Developing ...
A new study published in the American Journal of Gastroenterology found significant disparities in healthcare utilization among racial and ethnic groups with inflammatory bowel disease (IBD) in the US. Black Americans over 65 had nearly 1.5 times higher use of emergency department services compared to White counterparts, while Asian an...
A study using machine learning models found that people with IBD are at risk for premature death when developing other chronic health conditions earlier in life. Chronic conditions like arthritis, hypertension, and mood disorders were common causes of death among those with IBD.
A Mount Sinai-led team has discovered a link between gamma delta intraepithelial lymphocytes and the development of Crohn's disease. By analyzing a mouse model, they found that impaired communication between these cells led to inflammation in the lower small intestine.
New guidelines support safe and efficient use of JAK inhibitors for treating chronic inflammatory diseases like rheumatoid arthritis, psoriasis, and Crohn's disease. The updated consensus statement considers safety concerns, including cardiovascular disease and cancer risk, to ensure individualized treatment decisions.
A new study by Weill Cornell Medicine researchers has identified a potential biomarker for joint inflammation in Crohn's disease patients, the bacterium Mediterraneibacter gnavus. The study found that M. gnavus is associated with increased immune cell responses and disease activity scores in patients with joint inflammation.
A longitudinal study found that EBV infection predisposes people to develop Crohn's disease, with a five-to-seven-year delay between exposure and diagnosis. The study suggests that EBV may alter the immune system leading to Crohn's disease.
A new study led by the CIBEREHD group at Hospital Germans Trias demonstrates a significant improvement in monitoring and treatment of Crohn's disease patients. By analyzing calprotectin levels, patients can avoid unnecessary repeat colonoscopies.
The unfolded protein response (UPR) is a critical regulator of intestinal epithelial cell function, and its disruption contributes to inflammatory bowel diseases and colorectal cancer. X-box binding protein 1 (XBP1) plays a crucial role in maintaining IEC function.
A new surgical approach has shown significant impact in treating Crohn's disease by reducing the need for repeat surgery. The approach involves removing the mesentery, which adjoins the diseased intestine, and has been validated in an international trial.
Researchers at University of Gothenburg have identified a critical mechanism to slow down Crohn's disease progression by repairing the protective barrier of the gut. By reinforcing the gut's natural defenses, new drug targets may be developed to treat the disease.
Researchers at TUM have developed a new therapeutic approach combining dietary therapy with fecal microbiome transfer to sustain inflammation-free states in Crohn's disease patients. The study found that the gut microbiome changes as a result of dietary therapy contribute to treatment success.
A new study published in the Journal of Crohn's and Colitis reveals that vancomycin may be an effective treatment for people with inflammatory bowel disease (IBD) and autoimmune liver disease. The antibiotic achieved clinical remission in 80% of patients, with significant decreases in inflammatory markers and mucosal healing.
Crohn's & Colitis Congress showcases cutting-edge research on IBD treatment barriers, genetic factors, and cardiovascular safety. Key studies reveal significant financial sacrifices made by patients to access care and identify epigenetic clues for Crohn's disease development.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
Researchers at Uppsala University found that people with psoriasis have invisible inflammation in their small intestine, which can lead to gastrointestinal problems and an increased risk of developing Crohn's disease. Half of the study participants had a leaky gut, allowing bacteria and harmful substances to leak through the intestinal...
Early treatment with TNF inhibitors has been shown to prevent complications in kids with Crohn's disease, reducing the risk of perianal fistulas by 82%. The study found that anti-TNF drugs are specifically effective in preventing these debilitating complications, making them a recommended first-line therapy.
A study by Michigan Medicine researchers suggests that sulfur-producing bacteria may be behind lingering Crohn's disease symptoms, even in the absence of inflammation. The study found that these bacteria can lead to increased visceral hypersensitivity and altered intestinal permeability, contributing to persistent symptoms.
Research highlights the critical link between the body's circadian clock and inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis. Disruptions in circadian rhythms exacerbate inflammation, suggesting that aligning treatment strategies with natural biological cycles could improve patient outcomes.
A comprehensive analysis of pediatric IBD prevalence in the US reveals an increase of 22% for Crohn's disease and 29% for ulcerative colitis in the pediatric population. The study provides crucial data to inform healthcare policy, resource allocation, and future research priorities.
Researchers have reviewed the therapeutic potential of extracellular vesicles derived from mesenchymal stem cells in treating inflammatory bowel disease. The study highlights the immunomodulatory, pro-regenerative, and anti-apoptotic properties of these vesicles, which may offer a safer alternative to conventional therapies.
Researchers identify biomarker Ki67 that indicates whether treatment with vedolizumab will be successful. The biomarker can help predict which patients are more likely to respond to the form of treatment, allowing for more targeted use and potentially improving patient outcomes.
A team of researchers, including Binghamton University's Ahyeon Koh, is working on an innovative project to treat inflammatory bowel diseases like Crohn's and ulcerative colitis. The goal is to create a 'cell factory' in the body that can produce pharmaceuticals to alleviate symptoms.
Researchers from UT Arlington sequenced RNA genes of pythons, discovering conserved pathways in humans that are activated uniquely by these snakes. This knowledge helps explain intestinal regeneration and metabolism changes, offering potential therapeutic targets.